Menopur 600 IU powder and solvent for solution for injection

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Menopur 600 IU powder and solvent for solution for injection

Menotropin

Read the entire leaflet carefully before you start using this medicine , as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, since it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if it is an adverse effect not listed in this leaflet (see section 4).

Contents of the leaflet

1. What Menopur is and what it is used for
2. What you need to know before using Menopur
3. How to use Menopur
4. Possible side effects
5. How to store Menopur
6. Contents of the pack and other information

1. What Menopur is and what it is used for

Menopur is supplied as a powder that must be mixed with a liquid (solvent) before use. It must be administered as an injection under the skin.

The active substance in Menopur is highly purified and is known as menotropin. Menotropin is obtained from the urine of postmenopausal women and contains three hormones: follicle-stimulating hormone (FSH), human chorionic gonadotropin (hCG), and luteinizing hormone (LH).

hCG, extracted from the urine of pregnant women, may be added to contribute to the total bioactivity of LH.

FSH, hCG, and LH are natural hormones produced in women. They help the reproductive organs function normally.

Menopur is indicated for the treatment of infertility in the following situations:

• Women who are unable to become pregnant because their ovaries do not produce eggs (including polycystic ovary syndrome). Menopur is used in women who have been treated with a medicine called clomiphene citrate for their infertility, but this medicine has not worked.
• Women undergoing assisted reproductive technology (ART) programs (including in vitro fertilization/embryo transfer [IVF/ET], gamete intrafallopian transfer [GIFT], intracytoplasmic sperm injection [ICSI]). Menopur helps the ovaries to develop multiple egg sacs (follicles) where an egg can develop (multiple follicular development).
• Infertility in men with hypogonadotropic or eugonadotropic hypogonadism: in combination with human chorionic gonadotropin to stimulate spermatogenesis.

2. What you need to know before using Menopur

Before starting treatment with Menopur, you and your partner should be evaluated by a doctor to determine the causes of infertility. In particular, the following conditions should be checked so that the most appropriate treatment can be given:

• Dysfunction of the thyroid gland and adrenal cortex
• High levels of a hormone called prolactin (hyperprolactinemia)
• Tumors in the pituitary gland (a gland located at the base of the brain)
• Tumors in the hypothalamus (an area located below the part of the brain called the thalamus).

If you know you have any of the conditions listed above, please inform your doctor before starting treatment with Menopur.

Do not use Menopur if:

• you are allergic (hypersensitive) to menotropin or to any of the other components of Menopur listed in section 6.

In women:

• if you have a tumor in the uterus, ovaries, breasts, or certain areas of the brain such as the hypothalamus-pituitary region
• if you have enlarged ovaries or cysts not caused by polycystic ovary syndrome
• if you have malformations of the genital organs or uterus (womb)
• if you have vaginal bleeding of unknown cause
• if you have fibroids (benign tumors) in the uterus (womb)
• if you are pregnant or breastfeeding
• if you have premature menopause.

In men:

• If you have prostate carcinoma
• If you have a tumor in the testicles.

Warnings and precautions

If you experience:

• Abdominal pain
• Abdominal swelling
• Nausea
• Vomiting
• Diarrhea
• Weight gain
• Difficulty breathing
• Decreased urine output.

Contact your doctor immediately, even if symptoms develop several days after the last injection was administered. These may be signs of excessive ovarian activity, which could become severe.

If these symptoms become severe, infertility treatment must be discontinued and you should receive treatment in a hospital.

Following the recommended dose and careful monitoring of treatment will reduce the likelihood of experiencing these symptoms.

If you stop using Menopur, you may still experience these symptoms. Please contact your doctor immediately if you develop any of these symptoms.

While undergoing treatment with this medicine, your doctor will usually order ultrasounds and sometimes blood tests to monitor your response to treatment.

When being treated with hormones such as Menopur, the risk may increase of:

• Ectopic pregnancy (pregnancy outside the uterus) if you have a history of fallopian tube disease
• Miscarriage
• Multiple pregnancy (twins, triplets, etc.)
• Congenital malformations (physical defects present at birth).

Some women who have been treated with various infertility medications have developed tumors in the ovaries and other reproductive organs. It is not yet known whether treatment with hormones such as this medicine causes these problems.

Blood clots in blood vessels (veins or arteries) are more likely to occur in pregnant women. Infertility treatment may increase the likelihood of this happening, especially if you are overweight or have a known blood clotting disorder (thrombophilia), or if you or a family member (blood relative) has had clotting problems. Inform your doctor if you think this applies to you.

Use in children

Menopur has no appropriate indications for use in children.

Use of Menopur with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

No studies on drug interactions with Menopur have been conducted in humans.

When treating infertile men, menotropin and human chorionic gonadotropin may be administered simultaneously.

Clomiphene citrate is another medicine used in infertility treatment. If Menopur is used at the same time as clomiphene citrate, the effect on the ovaries may be increased.

Menopur may be used at the same time as Bravelle (another medicine used for infertility treatment). Please see section 3 “How to use Menopur”.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Menopur is not indicated under any circumstances for treating pregnant or breastfeeding women.

Driving and using machines

It is unlikely that Menopur will affect your ability to drive or use machines.

Important information about some of the components of Menopur:

Menopur contains less than 1 mmol of sodium chloride (23 mg) per dose and is therefore essentially sodium-free.

3. How to use Menopur

Follow exactly the administration instructions for Menopur given by your doctor.

If in doubt, consult your doctor or pharmacist again.

• Women who do not ovulate (do not produce eggs):

Treatment will begin within the first 7 days of the menstrual cycle (day 1 is the first day of the period). Treatment should be administered daily for at least 7 days.

The usual starting dose is 75–150 IU daily. This dose may be increased according to your response to treatment, up to a maximum of 225 IU per day. An individual dose should be administered for at least 7 days before the dose is adjusted by your doctor. The recommended dose increase is 37.5 IU per adjustment (and no more than 75 IU). The treatment cycle should be discontinued if there is no adequate response after 4 weeks.

When an optimal response is achieved, a single injection of another hormone called human chorionic gonadotropin (hCG), at a dose of 5,000 to 10,000 IU, will be administered 1 day after the last dose of Menopur. Sexual intercourse is recommended on the same day as hCG administration and the following day. Alternatively, intrauterine insemination may be performed (injection of sperm directly into the uterus). Your doctor should monitor your progress closely for at least 2 weeks after hCG administration.

Your doctor will monitor the effect of Menopur treatment. Depending on your progress, your doctor may decide to discontinue treatment with Menopur and not administer the hCG injection. In this case, you must use a contraceptive method (condom) or abstain from sexual intercourse until your next period begins.

ii. Women in assisted reproduction programs:

If you are also receiving treatment with GnRH agonists (a medicine that helps the hormone called Gonadotropin-Releasing Hormone (GnRH) to function), treatment with Menopur should begin approximately 2 weeks after starting the GnRH agonist treatment.

If you are also receiving treatment with GnRH antagonists, treatment with Menopur should begin on day 2 or 3 of the menstrual cycle (day 1 is the first day of the period).

Menopur should be administered daily for at least 5 days. The recommended starting dose of Menopur is 150–225 IU. This dose may be increased according to your response to treatment, up to a maximum of 450 IU per day. The dose should not be increased by more than 150 IU per adjustment. Treatment is generally not recommended for longer than 20 days.

If there are sufficient ovarian follicles, a single injection of a medicine called human chorionic gonadotropin (hCG) at a dose of up to 10,000 IU will be administered to induce ovulation (release of an egg).

Your doctor should monitor your progress closely for at least 2 weeks after hCG administration.

Your doctor will monitor the effect of Menopur treatment. Depending on your progress, your doctor may decide to discontinue treatment with Menopur and not administer the hCG injection. In this case, you must use a contraceptive method (condom) or abstain from sexual intercourse until your next period begins.

Infertility in men:

Initially, 1,000 to 3,000 IU of human chorionic gonadotropin is administered three times a week until normal serum testosterone levels are achieved.

Afterwards, a dose of Menopur of 75–150 IU (1–2 vials) is administered three times a week by intramuscular (IM) injection for several months.

Use in children

Menopur has no appropriate indications for use in children.

INSTRUCTIONS FOR USE:

If your doctor instructs you to self-inject Menopur, you must follow any instructions provided by your doctor.

The first injection of this medicine should be administered under the supervision of a doctor or nurse.

Menopur is supplied as a powder in a vial and must be dissolved with a solvent using a syringe before injection. The diluent to be used for reconstituting Menopur is provided in a pre-filled syringe.

Menopur 600 IU must be reconstituted with a pre-filled syringe containing the solvent prior to use.

After dissolving the powder with the solvent, the vial contains medication for several days of treatment, therefore you must ensure that you withdraw only the amount of medication prescribed by your doctor.

Your doctor has prescribed you a dose of Menopur in IU (international units). You must use one of the 9 administration syringes graduated in IU (FSH/LH) provided.

Follow the steps below:

1. Remove the protective cap from the powder vial and the rubber stopper from the pre-filled syringe containing the solvent (image 1).

2. Firmly attach the long, thin needle (reconstitution needle) to the pre-filled syringe containing the solvent, and remove the protective cap (image 2).

3. Insert the needle vertically through the center of the rubber stopper of the powder vial and slowly inject all the liquid to avoid bubble formation (image 3).

4. When the solvent is added, a slight overpressure is created in the vial. Therefore, release the syringe plunger so that it rises by itself for about 10 seconds. This will eliminate excess pressure in the vial (image 4).

Remove the syringe and the reconstitution needle.

1. The powder will dissolve rapidly (within 2 minutes), forming a clear solution. Although this usually occurs after only a few drops of solvent have been added, the full amount of solvent must be added. To assist dissolution of the powder, gently swirl the vial (image 5). Do not shake, as this may cause the formation of air bubbles.

Do not use the reconstituted solution if it contains particles or is not clear.

The vial of powder is now dissolved using the solvent syringe and is ready for use.

1. Take the administration syringe with the pre-attached needle and insert the needle vertically into the center of the vial. The administration syringe already contains a small amount of air, which should be injected into the vial above the liquid. Turn the vial upside down and withdraw the prescribed dose of Menopur into the administration syringe for injection (image 6).

REMEMBER: since the vial contains medication for several days of treatment, you must ensure that you withdraw only the amount of medication prescribed by your doctor.

1. Remove the syringe from the vial and withdraw a small amount of air from the syringe (image 7).

2. Gently tap the administration syringe so that all air bubbles collect at the top (image 8). Carefully push out all the air until the first drop of solution appears at the tip of the needle.

Your doctor or nurse will tell you where to inject yourself (e.g., front of the thigh, abdomen, etc.).

Before injection, clean the skin at the injection site with an alcohol swab.

1. For injection, pinch the skin to create a skin fold and insert the needle quickly at a 90-degree angle to the body. Push the plunger to inject the solution (image 9), then remove the syringe.

After removing the syringe, apply pressure to the injection site to control any bleeding. Gently massaging the injection site will help disperse the solution under the skin.

Do not throw used materials into the trash; they must be properly disposed of.

1. For subsequent injections with the reconstituted Menopur solution, repeat steps 6 to 9.

If you use more Menopur than you should. In case of overdose or accidental ingestion of the solution, consult your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medication and the amount used.

If you forget to use Menopur, do not use a double dose to make up for forgotten doses. Please inform your doctor or pharmacist.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, Menopur can cause adverse effects, although not everyone will experience them.

Treatment with Menopur may lead to high levels of ovarian activity, which can result in a condition called Ovarian Hyperstimulation Syndrome (OHSS), especially in women with polycystic ovaries. Symptoms include: abdominal distension and discomfort, nausea, vomiting, diarrhoea, and weight gain. In some severe cases of OHSS, rare complications have been reported, such as fluid accumulation in the abdomen, pelvis and/or pleural cavity, difficulty breathing, and decreased urine output.

Blood clot formation in blood vessels (thromboembolism) and ovarian torsion may also occur. If you experience any of these symptoms, contact your doctor immediately, even if they develop several days after the last injection.

Allergic reactions (hypersensitivity) may occur when using this medicine. Symptoms of such reactions may include: rash, itching, swelling of the throat, and difficulty breathing. If you experience any of these symptoms, contact your doctor immediately.

The following common adverse effects occur in between 1 and 10 out of every 100 treated patients:

• Abdominal pain
• Headache
• Nausea
• Abdominal bloating (fullness)
• Pelvic pain
• Ovarian hyperstimulation resulting in high levels of activity (Ovarian Hyperstimulation Syndrome)
• Local reactions at the injection site (such as pain, redness, bruising, swelling and/or irritation)

The following uncommon adverse effects occur in between 1 and 10 out of every 1,000 treated patients:

• Vomiting
• Abdominal discomfort
• Diarrhoea
• Fatigue
• Dizziness
• Fluid-filled sacs within the ovaries (ovarian cysts)
• Breast complications (including breast pain, breast tension, breast discomfort, nipple pain, and breast swelling)
• Hot flushes

The following rare adverse effects occur in between 1 and 10 out of every 10,000 treated patients:

• Acne
• Skin rash

In addition to the adverse effects listed above, the following adverse effects have been reported after marketing of Menopur, with unknown frequency:

• Vision disturbances
• Fever
• Feeling unwell
• Allergic reactions
• Weight gain
• Muscle and joint pain (e.g. back, neck, arms, and legs)
• Ovarian torsion as a complication of increased ovarian activity due to hyperstimulation
• Pruritus
• Urticaria
• Blood clots as a complication of increased ovarian activity due to hyperstimulation

Reporting of adverse effects

If you experience any adverse effects, talk to your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaRAM.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Menopur

Keep out of sight and reach of children.

Before reconstitution, store in the refrigerator (2°C – 8°C). Do not freeze. Store in the original packaging to protect from light.

After reconstitution, the solution may be stored for up to 28 days at a temperature not exceeding 25°C.

The reconstituted solution must not be administered if it contains particles or is not clear.

Do not use Menopur after the expiry date stated on the packaging after "EXP". The expiry date refers to the last day of the month indicated.

Medicines must not be disposed of via wastewater or household waste. Unused medicines and their containers should be returned to the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to properly dispose of unused medicines and their packaging. This will help protect the environment.

6. Package contents and other information

Composition of Menopur

The active substance is highly purified menotropin (human menopausal gonadotropin, hMG-HP), corresponding to 600 IU with follicle-stimulating hormone (FSH) bioactivity and 600 IU with luteinizing hormone (LH) bioactivity.

After reconstitution, 1 ml of reconstituted solution contains 600 IU of highly purified menotropin.

The other components of the powder are: lactose monohydrate, polysorbate 20, dibasic sodium phosphate heptahydrate (as buffer and for pH adjustment), and phosphoric acid (for pH adjustment).

The components of the solvent are: metacresol and water for injection.

Appearance of the medicinal product and contents of the container.

Menopur is a powder and solvent for injectable solution.

Menopur is a white to greyish compact lyophilized powder presented in a glass vial together with a pre-filled syringe containing the solvent, a clear colourless solution, for reconstitution, 1 needle for reconstitution, and 9 disposable graduated syringes marked in FSH/LH units with fixed needles for administration.

Marketing Authorization Holder and Manufacturer:

Marketing Authorization Holder

Ferring, S.A.U

C/ del Arquitecto Sánchez Arcas nº3, 1º

28040 Madrid

• Spain.

Manufacturer:

FERRING GmbH

Wittland 11,

D-24109 Kiel

GERMANY

This leaflet was approved in November 2025.

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/